Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
 
Register now or login to post to this thread.

Bioprogress (BPRG)     

scorpion - 13 Aug 2003 13:54

Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Janus - 28 Jun 2004 17:51 - 567 of 2372

He has sold 560,000 still has 3,437,093

AdieH - 28 Jun 2004 18:29 - 568 of 2372

Ok not so bad then he's entitled to get some cash, lol.

Big Al - 28 Jun 2004 18:36 - 569 of 2372

He's a bit slow getting rid of them if that's right....

.......unless he knows something no-one else does.

:-0

rayrac - 28 Jun 2004 21:54 - 570 of 2372

Urmmmm. Where did he B Muncaster, get the cash to buy shares in BPRG? Apparently they keep saying the directors put their houses in hock and used their credit cards to keep the company 'running' a while back.

10m shares had to be paid for from somewhere?

As has been said the sale of 560,000 shares doesn't look to be what most shareholders will appreciate, especially as it take him below the 3% threshold, he can if he wishes, sell without a declaration from now on I believe! I'm thankful I don't hold them!

Seymour Clearly - 28 Jun 2004 23:51 - 571 of 2372

As a Director I think he still has to say if he sells, the 3% is only if someone is building a stake but no personal involvment in the co. - someone correct me if I'm wrong.

Only 13000 posts on BPRG over the road since I last looked at the thread!

rayrac - 29 Jun 2004 11:19 - 572 of 2372

He's NOT a director SC. The 3% applies to every/anyone. He can do what he wants now, hence maybe, the sale of 560,000 and not 500,000?

He appears keen by that trade, to get below 3%? Ominous?

nematode - 29 Jun 2004 12:34 - 573 of 2372

Don't listen to this arsehole,he's from advfn and seemingly been told to piss off from there.All is well and expect rns tomorrow.

scotinvestor - 29 Jun 2004 12:42 - 574 of 2372

hope so nemo as i'm on a big loss on this as i bought at just more than 100p

Big Al - 29 Jun 2004 12:51 - 575 of 2372

Very ominous! ;-)

AdieH - 29 Jun 2004 12:57 - 576 of 2372

Thanks Nematode, lets keep fingers crossed for the RNS...

Big Al - 29 Jun 2004 15:29 - 577 of 2372

No disrespect to anyone, but this is a very bearish chart. The price is even well through the 200d SMA, which is a major indicator for choosing bull or bear. I use the settings below to trade. The dead cross coincided with the fall through 100p, which itself had been a strong support level.

BPRG is now at a critical stage IMO. If 60p goes (the congested area prior to the breakout), then 40p and even 20p may come very quickly indeed.

Any RNS will need to be very good indeed to turn this chart.

graph.php?size=Big&movingAverageString=1

Anyway, best of luck to you, but I'm afraid not for me.

Al

Aerotus - 29 Jun 2004 23:01 - 578 of 2372

Big Al, keep a close eye on the chart tomorrow ;)

hushpuppy - 29 Jun 2004 23:19 - 579 of 2372

Big Al
Am most impressed with the pretty chart. Hate to see it go to 20p as I'd be far too tempted to buy some more and I've got too many already. :-) or should it be :-(

Big Al - 30 Jun 2004 09:10 - 580 of 2372

hushpuppy - I might be tempted to buy there too, John. ;-))

Aerotus - will do! ;-0

elrico - 30 Jun 2004 10:19 - 581 of 2372

Conrad Windham (Guest Author)

April 7 2004

It is not an enviable position to be in, that is, of the analyst whose job it is to compile a report on BioProgress right now. Only this weekend I stumbled across an old announcement from March 2000, where BioProgress had signed an agreement with JT USA, and Dye Precision to develop a new type of paintball using the XGel technology. It was a reminder of just how revolutionary and extensive this technology truly is.

This article is not a stab at forecasting a value for the whole of BioProgress, but rather to concentrate on the recent acquisition of the edible film assets of Aquafilm. The completion of this acquisition was announced to the market on 1st April, and the acquired assets are now a wholly owned subsidiary of BioProgress called BioFilm LLC.

CEO Graham Hind already had a working relationship with Aquafilm prior to the acquisition, as the company had been a third party film supplier to BioProgress. Therefore when Hind was made aware that the owners of Aquafilm, who were in their late 60s and wished to retire, were prepared to sell the business he moved swiftly to secure the edible film division.

The terms of acquiring the edible film assets of Aquafilm look to be very shrewd indeed. The deal comprises an upfront payment of $3.5 million and $7.5 million as an earn-out on a $1/$1 basis against net profit. Full purchase completion is anticipated to be made by 2006.

It is worth taking a look at Aquafilms forecasts for the edible film division:

Year To 31st December
US $ Million 2004e 2005e 2006e 2007e
Revenue 8.8 16.5 28.9 48.1
Net Profit 3.2 5.2 9.1 16.1
Profit Margin 36% 32% 32% 34%

These forecasts are ideal for showing just how profitable BioProgress should be in three years time come 2007. The forecast of $16.1 million profit on $48.1 million of turnover equates, at todays exchange rate to 8.78 million. Ignore the XGel technologies and assume that BioProgress comprised just the edible film division of Aquafilm. Profit of 8.78 million equates to EPS of 7.8p and puts BioProgress on a 2007 PE of 13.

This forecast PE excludes both of the current XGel licensing agreements. When factoring in the licensing deal with FMC BioPolymer for NROBE which is expected to generate a minimum of $160 million of revenue to BioProgress over the first six years following commercialisation, we can begin to appreciate the potential revenues that BioProgress should be generating in just three years time.

Current customers of Aquafilm include the following:

Procter & Gamble The Vic Vapour Strip
Boots Vitamin Strips
Colgate Teeth Whitening
Pepsico Breath Freshening Strips
Reckitts Mouth Ulcer Strips
Home Market Foods Nutrastrips
Healthy Moments Spiderman

Hind has already thought of a new market for Aquafilm to target, pets. It has always been notoriously difficult to get an animal to swallow a tablet, but the chances are a meaty flavoured strip will go down well, perhaps even considered a treat by the animal.

The cost of acquiring Aquafilm and bringing it up to a high standard is not a massive drain on BioProgress cash resources. With the recent exercise of the warrants there was 18 million in the bank; 4 million of this will be spent on Aquafilm. $3.5 million on the initial purchase, $1 million of working capital and $3 million capital investment in order to secure full FDA Pharmaceutical plant approval to exploit the new WAFERTAB technology.

The next two months sees the launch of two of the new edible food strip products in America. Spiderman vitamin strips are being launched in May for the new Spiderman 2 movie, and Home Market Foods launch their Nutrastrips, available in different varieties such as Immune Boosting, Caffeinated, Vitamin or Energizing. Combined the sales forecast for these two products is $4.7 million. In the UK Boots have recently launched vitamin strips. Revenue from the new acquisition is already rolling in.

There is an interesting twist with the acquisition of the Aquafilm assets. BioProgress have a court case pending against Stanelco with regard to entitlement to key patents and patent applications in the portfolio of Stanelco. Although it should be noted that BioProgress are insulated from the costs by an insurance policy. Stanelco have a major contract with the R P Scherer division of Cardinal Health to develop its Ingel technology, the only place where Stanelco can get hold of the required film is Aquafilm. A clause in the contract with Stanelco allows Scherer to cancel its contract in July. It is now apparent why Stanelco pushed for a court date in September, the fact that it is set for July allows Scherer to break its ties with Stanelco, should it lose the court case.

The Aquafilm acquisition therefore strengthens the strategic position of BioProgress, brings in immediate revenues and profits, accelerates the development of WAFERTAB, and accelerates the film supply for FMC BioPolymer as well as accelerating the US film supply for TABWRAP. All in all then, a terrific acquisition which helps to highlight why BioProgress remains cheap.

It should be noted that Conrad holds shares in BioProgress.

Related links:

Bioprogress orginal feature

Results

BPRG FMC

October 3 2003

November 12 2003

December 3 2003

Febuary 19 2004

February 23 2004
http://www.lemminginvestor.com/BPRGconradWindham.html

elrico - 30 Jun 2004 10:21 - 582 of 2372

The Financial Press seem to be waking up and take notice of what our readers and Fillyaboots.com readers were already aware on June 1. Bulletin board gossip has been rife since Wendy Durham`s feature Naked Shorting appeared on LemmingInvestor and her home site Fillyaboots.com.

The Sunday Mail says that up to 150 small UK firms are being traded on the Berlin Stock Exchange without their consent, according to City brokers, prompting fears that the trade may be knocking share values in London.

Suspicion is growing that the German exchange is being used as a vehicle to exert selling pressure, thus drive down shares prices in London listed smaller companies. This has outrage some British companies who have noted the listing of their shares in Berlin, without the authority of the companies involved; furthermore, they are apparently powerless with regards requesting the de-listing of their shares.

Griffin Mining, one such company whose shares have fallen from 30p in February to 21p Fridays close, made an announcement last week about the trading of its shares in Berlin, suggesting this might explain the recent fall in its price.

Finance director Roger Goodwin told Financial Mail: Lawyers have been instructed to see what action we can take. Philip Davies, a corporate finance director at stockbroker Charles Stanley - Griffin's official adviser - said the mining group was not alone. "We have five clients on Aim whose shares are being traded in Berlin without their consent," he said. "A number of advisers are talking to each other to see what we can do."

Another AIM listed company, BioProgress was listed on the Berlin Bourse in April this year. Since May the shares have fallen from 125p to 69p at Fridays close, under heavy pressure from sellers following Berlin trading, not London as investors would have thought.

The UK's Financial Services Authority said it had no powers to intervene on behalf of British firms in Germany and had no plans to become involved.



Related Links:

New York Times
Penny-Stock Fraud, From Both Sides Now
By Diana B. Henriques
February 16, 2003

Inside Wall Street Online
Foul Play Among the UAL Shorts?
By Gene Marcial
October 8, 2002

Canada StockWatch
Chell Group's chairman nabbed in boiler room raid
by Brent Mudry
December 18, 2002
http://www.lemminginvestor.com/NakedShortingPart2.html?1088349639171

Janus - 30 Jun 2004 12:04 - 583 of 2372

BioProgress plc

('BioProgress' or 'the Company')

Statement re: Berlin-Bremen Stock Exchange


BioProgress plc, a provider of innovative delivery mechanisms for the
pharmaceutical oral dosage markets, has noted that its shares have been listed
on the Berlin-Bremen Stock Exchange without its consent. The Company and its
advisers are taking all available steps to delist BioProgress' shares from the
Berlin-Bremen Stock Exchange.


Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. This announcement contains certain 'forward-looking
statements' within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking statements.
The forward-looking statements in this release include statements addressing
future financial and operating results and the timing and benefits of the
reorganisation. Detailed information about factors pertinent to the business of
the company that could cause actual results to differ is set forth in the
Company's filings with the Securities and Exchange Commission. The Company is
under no obligation to (and expressly disclaim any such obligation to) update or
alter its forward-looking statements whether as a result of new information,
future events or otherwise.

- Ends -


For further information:
BioProgress plc
Graham Hind, Chief Executive Tel: +44 (0) 1354 655 674
grahamhind@bioprogress.com
www.bioprogress.com

Big Al - 30 Jun 2004 13:18 - 584 of 2372

This is becoming a bit of a joke. Never heard of a company getting listed without its consent.

Does anyone in this outfit really know what's going on?

Big Al - 30 Jun 2004 15:29 - 585 of 2372

Oh dear!

graph.php?movingAverageString=17%2C85%2C

Fred1new - 30 Jun 2004 16:47 - 586 of 2372

I don't like the chart, and I have a reasonable size holding already. BUT !!!!! having read their site board at www.bioprogress.com Stuck my kneck out and bought at 67.63. I think it is now better for me to go and lie down and check the price in a week or so.

My feelings the volumes are lowish and the underlying value of the company is the same as it was 3 weeks ago. I hope the shorters are having sleepless nights!!!!!!




"Due to anxiety!!"

Register now or login to post to this thread.